Eikon Therapeutics, Inc. (NASDAQ:EIKN) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Eikon Therapeutics, Inc. (NASDAQ:EIKN) have received a consensus rating of “Hold” from the eight research firms that are presently covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, one has given a hold recommendation and five have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $25.20.

EIKN has been the subject of a number of recent research reports. Wedbush cut their target price on Eikon Therapeutics from $7.00 to $5.00 and set an “underperform” rating for the company in a research note on Tuesday, May 12th. Cantor Fitzgerald reissued an “overweight” rating on shares of Eikon Therapeutics in a research report on Tuesday, June 2nd. Wall Street Zen lowered shares of Eikon Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, April 5th. Finally, Weiss Ratings began coverage on shares of Eikon Therapeutics in a research report on Monday, June 1st. They set a “sell (e-)” rating for the company.

Eikon Therapeutics Stock Down 5.1%

EIKN stock opened at $9.01 on Thursday. The firm has a 50 day moving average of $10.19. The stock has a market capitalization of $487.79 million and a price-to-earnings ratio of -3.66. Eikon Therapeutics has a 1 year low of $7.90 and a 1 year high of $17.40.

Eikon Therapeutics (NASDAQ:EIKN) last posted its quarterly earnings results on Monday, March 30th. The company reported ($26.23) EPS for the quarter.

About Eikon Therapeutics

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications.